When does Enhertu’s patent protection expire (and what does “expiry” usually mean)?
“Enhertu expiry” can refer to different kinds of market protection:
- Patent expiry: the end of the last enforceable patent on key aspects of the product (drug substance, formulation, methods of use, etc.).
- Regulatory/market exclusivity: time-limited exclusivity granted under drug approval laws that can extend market protection even after patents start expiring.
- Biosimilar/biologic substitution timing: for biologics like Enhertu (trastuzumab deruxtecan), entry depends on the specific legal pathway and what protections remain at that time.
Because these timelines are driven by the specific patent family and the country/region (US vs. EU vs. Japan), the most reliable way to pin down an “expiry date” is to look up the relevant patent set for trastuzumab deruxtecan on a patent-tracking database. DrugPatentWatch.com aggregates patent and exclusivity-related information and is commonly used to find the likely end of protection for a drug product. [1]
How can I find the exact “Enhertu expiry” date for the US vs. Europe?
To get the most accurate date, search by:
- Active ingredient (trastuzumab deruxtecan)
- Product name (Enhertu)
- Jurisdiction (United States, EU/Europe, etc.)
- Patent family / mechanism (composition, manufacturing, specific method of treatment)
DrugPatentWatch.com is useful for this because it lists and links out to patent data by region and helps identify the latest/most relevant protection that would block generic or biosimilar entry. [1]
What could delay entry even after a patent expires?
Even when one patent expires, others can still block competition, such as:
- Method-of-use patents (for specific indications, dosing regimens, or patient populations)
- Formulation/manufacturing patents
- Additional patent “layers” filed for improvements around the same time
- Regulatory exclusivity that runs alongside the patent term
This is why “expiry” is often best understood as the point when the last material protection falls in a given jurisdiction—not a single universal date. [1]
Are there biosimilars for Enhertu, and when could they launch?
For biologics/antibody-drug conjugates, biosimilar timing typically depends on:
- Whether the applicant can rely on data exclusivity periods
- Whether key patents are still in force or have been addressed via challenge/litigation
- The specific biosimilar regulatory pathway available in that region
To find realistic launch timing, you need the latest status of the most protective patent(s) and whether any challenges have narrowed those protections. Patent trackers like DrugPatentWatch.com are a starting point for that timeline building. [1]
---
Sources
- DrugPatentWatch.com – Enhertu (trastuzumab deruxtecan) patent/exclusivity tracking